共 56 条
[1]
Garzón JR(2011)Pharmacokinetics and pharmacodynamics of antimicrobials: a report of patients with neutropenia and fever Rev Chilena Infectol 28 537-545
[2]
Cuervo MS(2012)Pharmacokinetic and pharmacodynamic issues for antimicrobial therapy in patients with cancer Clin Infect Dis 54 1785-1792
[3]
Gómez J(2011)Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of America Clin Infect Dis 52 e56-e93
[4]
Cortés JA(1985)Moxalactam and Piperacillin: a study of in vitro characteristics and pharmacokinetics in cancer patients Infection 13 20-26
[5]
Theuretzbacher U(1989)A prospective evaluation of optimal sampling theory in the determination of the steady-state pharmacokinetics of piperacillin in febrile neutropenic cancer patients Clin Pharmacol Ther 45 635-641
[6]
Freifeld AG(2002)Guidelines for chronic kidney disease: evaluation, classification and stratification Am J Kidney Dis 39 S1-S266
[7]
Bow EJ(1987)Clinical and statistical validity of conventional prognostic factors in predicting short-term survival among cirrhotics Hepatology 7 660-664
[8]
Sepkowitz KA(2002)Comparative pharmacokinetic and pharmacodynamic profile of piperacillin/tazobactam 3.375G Q4H and 4.5G Q6h Chemother 48 59-63
[9]
Boeckh MJ(1994)Pharmacodynamics of piperacillin alone and in combination with tazobactam against piperacillin-resistant and -susceptible organisms in an in vitro model of infection Antimicrob Agents Chemother 38 2351-2356
[10]
Ito JI(2009)Steady-state pharmacokinetics and pharmacodynamics of piperacillin/tazobactam administered via prolonged infusion in hospitalised patients Internat J Antimicrob Agents 34 429-433